• Skip to main content
  • Skip to footer

Amicus

  • Home
  • About Fabry
    • Fabry disease pathophysiology and natural history
    • Prevalence of Fabry disease
    • GLA gene mutations and inheritance
    • Clinical manifestations of Fabry disease
    • Diagnosis of Fabry disease
    • Management of Fabry disease
  • About Pompe
    • Pompe disease pathophysiology and natural history
    • Prevalence of Pompe disease
    • GAA gene mutations and inheritance
    • Clinical manifestations of Pompe disease
    • Diagnosis of Pompe disease
    • Management of Pompe disease
  • Your Specialty
    • Nephrology
      • Renal pathophysiology in Fabry disease
      • When should a nephrologist suspect Fabry disease
      • Management of Fabry disease
    • Cardiology
      • Cardiac pathophysiology in Fabry disease
      • When should a cardiologist suspect Fabry disease
      • Management of Fabry disease
    • Neuropsychology and ophthalmology
      • Pathophysiology and progression in Fabry disease
      • Neurology and Fabry disease
      • Psychology and Fabry disease
      • Ophthalmology and Fabry disease
      • When should you suspect Fabry disease?
      • Management of Fabry disease
    • Respiratory
      • Respiratory pathophysiology in Pompe disease
      • When should a respiratory specialist suspect Pompe disease?
      • Management of Pompe disease
    • Neurology
      • Pathophysiology of muscle damage
      • When should a neurologist suspect Pompe disease?  
      • Management of Pompe disease
  • Resources
    • All Resources
    • Latest Blog
  • Find a specialist centre

Management of Pompe disease

Neurology

Management of Pompe disease

As a rare disease, the understanding and management of Pompe disease continues to evolve as cumulative data becomes available. Amicus’ own medical information, as well as country regional guidelines, are based on current accepted literature. Guidance and text on disease epidemiology, assessments and treatment has been primarily taken from the few key academic references that form the current understanding and expert consensus on Pompe disease.


The appropriate management of Pompe disease requires a skilled multidisciplinary team and individualised decision making. Routine assessments and monitoring are key in the management of Pompe disease, with testing repeated at least every three months, depending on the age of the patient. Baseline values should always be obtained.1 

The management options for manifestations of late-onset Pompe disease are summarised below.

  • Routine vaccinations
  • Care should be taken with myorelaxant drugs and central nervous system depressants
  • No contraindications associated with general anaesthesia
  • Muscle strengthening and therapeutic exercise
  • Stretching, correction of improper positioning and use of orthotic devices (splints, walkers, canes, wheelchairs) to limit contracture and deformity
  • Surgical intervention for progressive spinal deformities
  • Supplements (vitamin D and calcium) and bisphosphonate for patients with osteoporosis
  • Low oxygen levels, obstructive sleep apnoea and hypoventilation can all be managed with oxygen therapy and/or positive pressure ventilation
  • Sedatives should be avoided, and treatment of respiratory infections should be early and aggressive
  • For patients with impaired secretion clearance due to weakened cough, bronchodilators can be used alongside airway clearance techniques, assisted coughing manoeuvres and inspiratory muscle training
  • Bronchodilators and corticosteroids are useful if the patient is also asthmatic
  • Chewing and swallowing problems can cause nutritional issues, so a high-protein and low-carbohydrate diet is recommended
  • Vitamin and mineral supplements
  • Thickeners to make swallowing liquids more manageable
  • Exercises to improve swallowing (supervised by a therapist trained in neuromuscular disorders)

Currently, enzyme-replacement therapy is the only class of disease modifying drug approved for the treatment of Pompe disease.3

If you suspect Pompe disease, referral to nominated ultra-specialist centre is essential so that patients can access full genetic testing and access to disease-specific therapies. Please refer to our ‘Find a specialist centre’ page to find out more.

Learn more

NP-NN-GB-00031223
October 2024

  1. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267-288.
  2. Barba-Romero MA, Barrot E, Bautista-Lorite J, et al. Clinical guidelines for late-onset Pompe disease. Rev Neurol. 2012;54(8):497-507.
  3. Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319-333.

2.
When should a neurologist suspect Pompe disease?

This non-promotional website is intended for UK Healthcare Professionals only.

Footer

Amicus is committed to providing medical education for UK healthcare professionals. This website is a non-promotional site developed and funded by Amicus.

Menu
Home
About Fabry
About Pompe
Nephrology
Cardiology
Neuropsychology and Ophthalmology
Respiratory
Neurology
Resources
Find a Specialist Centre

Company
About Amicus

Help
Contact us

© Amicus Education 2024. All rights reserved | Amicus therapeutics UK LTD One Globeside, Fieldhouse Lane, Marlow SL7 7HZ United Kingdom | Company registration no. 05541527 | NP-NN-UKI-00090325 March 2025 Privacy policy | Cookie policy | Terms of use